Employees: 38
Size Onconic Therapeutics (476060.KS) is a South Korea Health Care company (Biotechnology) with a market value of $368M, the 426th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩10,550 on 18 Nov 2026.
Performance Over six months the shares fell 49.3%, against -23.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 179.3% over the last twelve months (peer median +6.3%); the operating margin is 21.1% (peer median -2.0%).
Valuation It trades at 5.2× enterprise value to sales against a peer median of 2.6× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +725%, so the hurdle is -725 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 48.6 points above its cost of capital (5.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩82.2B | ₩53.4B | ₩14.8B | ₩21.1B | ₩95.0M |
| Revenue growth | — | +260% | -30% | +22,064% | — |
| Gross profit | ₩37.2B | ₩25.5B | ₩8.53B | ₩19.3B | n/a |
| EBITDA | ₩17.9B | ₩13.1B | -₩4.35B | ₩2.69B | -₩14.6B |
| Net income | ₩24.3B | ₩15.8B | -₩8.09B | ₩1.68B | -₩14.4B |
| Free cash flow | ₩16.5B | ₩11.1B | -₩7.98B | ₩2.98B | -₩17.5B |
| Capital expenditure | ₩317M | ₩303M | ₩141M | ₩1.16B | ₩2.58B |
| Total debt | ₩271M | ₩126M | ₩308M | ₩14.1B | ₩12.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 476060.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.4% | -5.4% | 3rd lowest of 20 |
| 6-month return | -49.3% | -23.6% | lowest of 20 |
| Distance from 52-week high | -63.5% | -47.2% | 4th lowest of 20 |
| Revenue growth (TTM) | +179.3% | +6.3% | 4th highest of 16 |
| Operating margin | 21.1% | -2.0% | 6th highest of 16 |
| EV / Sales | 5.2× | 2.6× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 0.6% | 4.7% | 3rd least demanding of 6 |
| Growth delivered (Del g) | +725.2% | +11.9% | highest of 6 |
| Hurdle (Req g minus delivered) | -724.6 pp | +14.3 pp | least demanding of 6 |
| ROIC minus cost of capital | +48.6 pp | -9.2 pp | highest of 16 |
| EV / EBITDA | 23.8× | 5.8× | 2nd most expensive of 8 |
| Net debt / EBITDA | -3.5× | -2.3× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |